Director Deborah Birx resigns from Innoviva board to become CEO of majority-owned Armata Pharmaceuticals

Innoviva, Inc.

Deborah L. Birx resigned from the Board and Audit Committee effective July 10, 2023.
She accepted the CEO position at Armata Pharmaceuticals, a majority-owned Innoviva subsidiary.
Resignation was not due to any disagreement with the Company's operations, policies, or controls.
No other Board changes or disagreements disclosed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Deborah L. Birx

member of the Board of Directors and chair of the Audit Committee

INVA · Innoviva, Inc.

Effective: 2023-07-10
Filed: July 11, 2023, 7:59 PM ET

On July 10, 2023, Deborah L. Birx, a member of the Board of Directors of Innoviva, Inc. (the “Board”) and chair of the Audit Committee, resigned from the Board, including the committees of the Board of which she is a member, effective as of July 10, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Deborah L. Birx resigned as member of the Board of Directors and chair of the Audit Committee at Innoviva, Inc..

Action: resigned
Role: member of the Board of Directors and chair of the Audit Committee

Exact text from the filing

On July 10, 2023, Deborah L. Birx, a member of the Board of Directors of Innoviva, Inc. (the “Board”) and chair of the Audit Committee, resigned from the Board, including the committees of the Board of which she is a member, effective as of July 10, 2023

View on SEC.gov

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-079823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.